• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B

    2/12/24 12:30:46 PM ET
    $ANTX
    $BIG
    $BMR
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Department/Specialty Retail Stores
    Consumer Discretionary
    Get the next $ANTX alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday.

    The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500 also rose, gaining, 0.30% to 5,041.87.

    Check This Out: Caterpillar, Marathon Petroleum And More On CNBC's 'Final Trades'

     

    Leading and Lagging Sectors

     

    Energy shares rose by 1.1% on Monday.

    In trading on Monday, health care shares fell by 0.1%.

     

    Top Headline

     

    Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion.

    The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio.

     

    Equities Trading UP

     

    Beamr Imaging Ltd. (NASDAQ:BMR) shares shot up 975% to $22.70 after the company announced it will present its joint research relating to automated video modernization with NVIDIA at the ACM Mile-High-Video 2024 conference.

    Shares of ContextLogic Inc. (NASDAQ:WISH) got a boost, surging 46% to $6.59 after the company announced an agreement to sell substantially all of its operating assets and liabilities to Qoo10 for approximately $173 million in cash.

    Millennium Group International Holdings Limited (NASDAQ:MGIH) shares were also up, gaining 500% to $6.18 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday.

     

    Equities Trading DOWN

     

    AN2 Therapeutics, Inc. (NASDAQ:ANTX) shares dropped 75% to $5.04 after the company announced it will voluntarily pause enrollment in the Phase 3 part of the Phase 2/3 pivotal clinical trial evaluating epetraborole in treatment-refractory MAC lung disease.

    Shares of WiSA Technologies, Inc. (NASDAQ:WISA) were down 37% to $0.05. WiSA Technologies priced 153,840,000 unit offering for gross proceeds of $10 million.

    Big Lots, Inc. (NYSE:BIG) was down, falling 31% to $3.72 after the company reported preliminary fourth-quarter results.

    Also Check This Out: Jim Cramer Says This Construction Giant Is 'So Good' And 'Goes Higher'

     

    Commodities

     

    In commodity news, oil traded down 0.2% to $76.69 while gold traded down 0.4% at $2,029.70.

    Silver traded up 0.4% to $22.675 on Monday while copper rose 0.9% to $3.7150.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.54%, London’s FTSE 100 rose 0.01% while Spain’s IBEX 35 Index rose 0.89% The German DAX rose 0.65% French CAC 40 rose 0.55% while Italy’s FTSE MIB Index gained 0.97%.

    The BNP Paribas Real Estate Construction PMI in Ireland edged higher to 45.9 in January from December’s reading of 45.1.

     

    Asia Pacific Markets

     

    Asia Pacific markets closed lower on Monday, with India’s S&P BSE Sensex falling 0.60% and Australia’s S&P/ASX 200 falling 0.39%.

     

    Economics

     

    The U.S. Treasury statement for January will be released at 2:00 p.m. ET.

    Now Read This: How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q4 Print

    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX
    $BIG
    $BMR
    $CBAY

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Gilead Sciences Inc.
    $GILD
    1/7/2026$145.00Buy
    UBS
    Gilead Sciences Inc.
    $GILD
    11/24/2025$140.00Buy
    Truist
    Gilead Sciences Inc.
    $GILD
    11/13/2025$140.00Sector Outperform
    Scotiabank
    Gilead Sciences Inc.
    $GILD
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    Gilead Sciences Inc.
    $GILD
    8/8/2025$127.00Hold → Buy
    Truist
    Gilead Sciences Inc.
    $GILD
    7/25/2025$133.00Hold → Buy
    Needham
    Gilead Sciences Inc.
    $GILD
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ANTX
    $BIG
    $BMR
    $CBAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $66.64 and sold $4,324,228 worth of shares (28,000 units at $154.44), decreasing direct ownership by 2% to 120,288 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/18/26 5:22:54 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Dickinson Andrew D sold $463,290 worth of shares (3,000 units at $154.43), decreasing direct ownership by 2% to 167,779 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/18/26 5:11:41 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cain Wettan Keeley M claimed ownership of 3,944 shares (SEC Form 3)

    3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/12/26 7:26:43 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    5/29/25 4:17:48 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Readnour Robin Shane bought $86,708 worth of shares (60,000 units at $1.45) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    12/10/24 8:46:19 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Gilead Sciences with a new price target

    UBS resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $145.00

    1/7/26 9:10:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Gilead Sciences with a new price target

    Truist resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $140.00

    11/24/25 8:41:38 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics de

    2/17/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

    2/10/26 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by AN2 Therapeutics Inc.

    SCHEDULE 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)

    2/17/26 6:54:12 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Millennium Group International Holdings Limited

    6-K - Millennium Group International Holdings Ltd (0001903995) (Filer)

    2/13/26 4:59:53 PM ET
    $MGIH
    Publishing
    Consumer Discretionary

    SEC Form 13F-HR filed by Gilead Sciences Inc.

    13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)

    2/12/26 4:36:53 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANTX
    $BIG
    $BMR
    $CBAY
    Financials

    Live finance-specific insights

    View All

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

    2/10/26 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

    Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion for Full Year 2025 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2025. "Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "In 2026, our potential new launches include two cancer therapies and an additional HIV

    2/10/26 4:01:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BIG
    $BMR
    $CBAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by WiSA Technologies Inc.

    SC 13G - WISA TECHNOLOGIES, INC. (0001682149) (Subject)

    11/14/24 5:27:55 PM ET
    $WISA
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:29:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:16:45 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care